Identifying Molecular Drivers of Cancer
May 24, 2018 updated by: Avera McKennan Hospital & University Health Center
The primary aim of this study is to identify drivers of cancer by performing comprehensive genetic, proteomic, and metabolomic characterization of patient samples as a basis for understanding the underlying cause of disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study involves looking at the DNA, RNA, proteins, and metabolites in blood and tissue samples collected from subjects and linking them to their health information.
By doing so, researchers hope to discover the underlying molecular causes of human diseases with the hope that this information can be used for the development of diagnostic tests and more effective treatments.
Study Type
Observational
Enrollment (Actual)
579
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Avera Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients who have been diagnosed with cancer
Description
Inclusion Criteria:
- Patients diagnoses with cancer but healthy enough to undergo a biopsy procedure
- Between the ages of 18 and 100
Exclusion Criteria:
- Patients who are pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Molecular profile
Molecular profiled group receiving treatment based on genetics
|
Patients and their treating physician will obtain the patient's genetic risk assessment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Genetic profiling
Time Frame: Up to 15 years
|
To determine genetic changes associated with the development and growth of human disease.
This should lead to better ways to detect, prevent, and treat a wide variety of human health conditions, including cancer.
|
Up to 15 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Brian Leyland-Jones, Avera McKennan Hospital & University Health Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2014
Primary Completion (Actual)
May 22, 2018
Study Completion (Actual)
May 22, 2018
Study Registration Dates
First Submitted
June 9, 2015
First Submitted That Met QC Criteria
June 10, 2015
First Posted (Estimate)
June 12, 2015
Study Record Updates
Last Update Posted (Actual)
May 25, 2018
Last Update Submitted That Met QC Criteria
May 24, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- AMEM-2014-CCD001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.